EMEA-002722-PIP01-19-M02

Table of contents

Key facts

Active substance
Etranacogene dezaparvovec
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0380/2022
PIP number
EMEA-002722-PIP01-19-M02
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of Haemophilia B
Route(s) of administration
Intravenous use
Contact for public enquiries
CSL Behring GmbH

Email: PIP.CSLBehring@cslbehring.com
Tel. +49 6421392355
 

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating